The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Subscribe To Our Newsletter & Stay Updated
